To further assess the anti-inflammatory effect of BTP2 on the breast cancer cells, we examined whether the LPS-induced upregulation of the inflammatory cytokines IL-6 and IL-8 in the MDA-MB-231 cells would be affected by the BTP2 treatment. Here, IL6 is linked to breast cancer.